Zinc supplementation for patients with acute myocardial infarction

Zinc supplementation for patients with acute myocardial infarction - Zinc for MI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030232

Enrollment

Registered

2017-12-03

Start date

2017-12-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction

Interventions

Zinc acetate 25 mg twice dairy, 3 days Conventional therapy Conventional therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age >20years obtain written informed consent success the primary PCI

Exclusion criteria

Exclusion criteria: (1)Hepatic cirrhosis (2)Dialysis (3)Inflammatory bowel disease (4)Chronic pancreatitis (5)After enterectomy or pancreaticoduodenectomy (6)Systemic inflammatory disease (7)Sickle cell anemia (8)Asthma, allergy of Gadolinium, MRI-none compatible pacemaker implanted (9)allergy of Zinc acetate (10) Patients with CTO in non-infarct related artery

Design outcomes

Primary

Measure	Time frame
Length of stay in the coronary care unit Length of hospitalization stay Infarct size, LVEF evaluated by MRI	—

Secondary

Measure	Time frame
The rate of requiring specific ancillary devices such as a temporary pacemaker, intra-aortic balloon pump (IABP), invasive and non-invasive positive pressure ventilation or venoarterial extracorporeal membrane oxygenation (VA-ECMO) LVEF, serum CK, CK-MB,BNP level all-cause and cardiovascular mortality	—

Countries

Japan

Contacts

Public ContactToshitaka Okabe

Showa University Northern Yokohama Hospital Division of Cardiology and Cardiac Catheterization Laboratories

alone_with_music@hotmail.com045-949-7000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026